FDA Grants Approval for Mylan's Liraglutide ANDA213155
The FDA has granted approval for Mylan's Abbreviated New Drug Application (ANDA) for Liraglutide.
Asset / Drug
Drug and asset intelligence for Liraglutide with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
GLP-1 Agonist
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.